A Study of RAY1225 in Participants With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT06254274
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 210 participants
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Registry
-
NCT06254274
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06254274. Randomized; double masking; primary purpose treatment. Start 2024-02-26 (actual); primary completion 2025-07-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of RAY1225 in Participants With Type 2 Diabetes
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- RAY1225
- Intervention (Drug)
- Placebo
- Lead sponsor
- Guangdong Raynovent Biotech Co., Ltd
Record details
- Record id
cardio:ct-nct06254274- Content hash
a955610fc760f616a24c30867ab39ccdd6c23b355b2afa14e9b31e1eaa1c981d